Why the study?
Does pharmacological manipulation of adrenal RAS affect aldosterone secretion in sodium-restricted rats?
Does pharmacological manipulation of adrenal RAS affect aldosterone secretion in sodium-restricted rats?
The adrenal renin-angiotensin system plays a role in regulating aldosterone secretion under conditions of prolonged stimulation such as sodium restriction.
Answers are grounded in this paper and cite their sources.
Extends preclinical evidence for adrenal RAS in aldosterone regulation under sodium restriction; leaves open human translation.
This study examined the effect of the pharmacological manipulation of adrenal renin-angiotensin system (RAS) on aldosterone secretion from in situ perfused adrenals of rats kept on a normal diet and sodium restricted for 14 days. Neither the angiotensin-converting enzyme inhibitor captopril nor the nonselective angiotensin II receptor antagonist saralasin and the AT(1) receptor-selective antagonist losartan affected basal aldosterone output in normally fed rats. In contrast, they concentration dependently decreased aldosterone secretion in sodium-restricted animals, with maximal effective concentration ranging from 10(-7) to 10(-6) M. Captopril (10(-6) M), saralasin (10(-6) M), and losartan (10(-7) M) counteracted aldosterone response to 10 mM K(+) in sodium-restricted rats but not in normally fed animals. Collectively, these findings provide evidence that adrenal RAS plays a role in the regulation of aldosterone secretion, but only under conditions of prolonged stimulation of zona glomerulosa probably leading to overexpression of adrenal RAS.
No takes yet. Share an insight, caveat, or question.
Mazzocchi et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: